New data from Arcutis Pharmaceuticals highlights the effectiveness of ZORYVE cream in treating symptoms of atopic dermatitis in babies. The study demonstrates that ZORYVE, a topical cream, significantly reduces inflammation, itching, and skin irritation associated with infantile atopic dermatitis. This breakthrough provides a promising treatment option for infants suffering from this common chronic skin condition. The clinical data supports ZORYVE’s safety and efficacy, offering parents and healthcare providers a new therapeutic tool. With atopic dermatitis affecting many young children, ZORYVE’s positive results mark an important advancement in pediatric dermatology. These findings pave the way for broader use of ZORYVE cream in managing infant skin health. Overall, this data bolsters confidence in ZORYVE as a valuable solution for improving the quality of life for infants with atopic dermatitis.
PluangNew data shows Sharp Drop in Share Trading Volume as CBK Reports Market Slowdown
November 14, 2026
New data released by the Central Bank of Kenya (CBK) reveals a significant decline in share trading activity, highlighting investors’ cautious stance in the current